SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Equip EHV1,4 suspension for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1.5 ml dose contains:

Active substances:
EHV_1, strain 438/77, inactivated: RP ≥ 1*
EHV_4, strain 405/76, inactivated: RP ≥ 1*

* Relative Potency ELISA compared to a reference vaccine which has been shown to be efficacious in horses.

Adjuvant:
Carbopol 934P 6 mg

Excipients:

Qualitative composition of excipients and other constituents
Disodium hydrogen phosphate
Sodium dihydrogen phosphate
Water for injection

Colourless to slightly pink/orange opaque suspension

3. CLINICAL INFORMATION

3.1 Target species

Horses.

3.2 Indications for use for each target species

For active immunisation of horses to reduce clinical signs due to infection with Equine Herpesvirus 1 and 4 and to reduce abortion caused by EHV-1 infection.

3.3 Contraindications

None.

3.4 Special warnings

Vaccinate healthy animals only.

3.5 Special precautions for use

Special precautions for safe use in the target species:The vaccine may not be effective in animals incubating the disease at the time of vaccination.
In the event of an allergic or anaphylactic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously (e.g. dexamethasone sodium phosphate), adrenaline intramuscularly or antihistamine intramuscularly. Animals that have received immunosuppressive drugs (e.g. glucocorticoids) should not be vaccinated until an interval of at least 4 weeks has elapsed.
Syringes and needles should not have been sterilised chemically or be above ambient temperature. Do not use chemicals to disinfect or sterilise the skin.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Not applicable.

Special precautions for the protection of the environment:
Not applicable.

3.6 Adverse events

Horses:

Very common (>1 animal / 10 animals treated):	Injection site swelling[1]
Common (1 to 10 animals / 100 animals treated):	Elevated temperature[2]
Rare (1 to 10 animals / 10,000 animals treated):	Stiff gait Anorexia, Lethargy
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Hypersensitivity reaction[3]

[1] Transient. Up to 5 cm in diameter, disappearing within a few to 6 days post vaccination.
[2] Transient. Up to 2 days following dosing not exceeding 1.7°C.
[3] Appropriate treatment is recommended / treat symptomatically.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy:
Can be used during pregnancy.

3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

3.9 Administration routes and dosage

One dose per horse to be administered by deep intramuscular injection.

Primary course: A single dose should be administered from 5 months of age followed by a second injection after an interval of 4 to 6 weeks.

In the event of increased infection risk, for example when a foal had consumed insufficient colostrum or there is a risk of early exposure to field infections with EHV-1 or EHV-4, earlier vaccination may be given. In these circumstances, the foal should receive a single dose from 3 months of age followed by the above mentioned full primary vaccination course.

Booster: Following completion of the primary course, a single dose should be administered every 6 months.

Use in pregnant mares: To reduce abortion due to EHV-1 infection, pregnant mares should be vaccinated during the 5th, 7th, and 9th month of pregnancy with a single 1.5 ml dose on each occasion.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No adverse reactions exceeding those discussed in section 3.6 were recorded following administration of an overdose.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Zero days.

4. IMMUNOLOGICAL INFORMATION

4.1 ATCvet code: QI05AA05

To stimulate active immunity against equine herpesvirus 1 and 4.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Do not mix with any other veterinary medicinal product.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: use immediately.

5.3 Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Store in the original package.
Protect from light.

5.4 Nature and composition of immediate packaging

Single dose vials (1.5 ml).
Container: Type 1 glass Ph. Eur.
Closure: Chlorobutyl rubber stopper PH 21/50 (Ph. Eur.). Aluminium crimp cap.

Pack sizes: 2, 10 and 50 dose packs.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis UK Limited

7. MARKETING AUTHORISATION NUMBER

Vm 42058/5162

8. DATE OF FIRST AUTHORISATION

14 December 1994

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

August 2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

Gavin Hall
Approved: 23 October 2025